Browsing tag:

Anthracyclines


Exemplary results in the 2012 Phase III trial coined EMILIA has led Roche Pharmaceuticals to initiate additional Phase III trials evaluating trastuzumab emtansine. The New Year brings registration trials for newly diagnosed as well as previously treated metastatic HER2-positive breast cancer patients. Trastuzumab will be evaluated in this 2013 study for three settings in earlier-stage[…]

Read More

The latest headline is daunting, with the World Health Organization’s International Agency for Research on Cancer announcing a 75 percent increase in cancer cases worldwide by 2030. This astounding prediction, published in Reuters on June 1, 2012 offered an unfortunate reality, based on data from GLOBOCAN. Causes are thought to be poor lifestyle choices worldwide,[…]

Read More

Pixantrone maleate, CAS Number 146675-97-8, is an anthracenedione anthracycline derivative, developed by Cell Therapeutics Incorporated. Pixantrone maleate is used for treatment of patients with non-Hodgkin’s lymphoma. LGM Pharma is a provider of pixantrone maleate for research and development purposes. As a promising treatment for aggressive non-Hodgkin’s lymphoma, pixantrone maleate is well tolerated when substituted for[…]

Read More

In the recent decades, women’s health has taken center stage. No longer hidden in obscurity, breast cancer emerged as a growing concern for women all over the world. The disease does not just strike women, it affects children and men as well, albeit indirectly. The role of the woman as a mom and earning partner[…]

Read More